|
Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE. |
|
|
Leadership - Sace Medhealth |
Stock and Other Ownership Interests - Sace Medhealth |
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; Celgene; Guardant Health; Ipsen; Lilly; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Roche; VCN Biosciences |
Speakers' Bureau - Amgen; Novartis; Roche |
|
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Novartis; Roche |
|
|
Consulting or Advisory Role - Bayer; Celgene; Merck; MSD Oncology; Roche; Servier; Shire |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Merck |
|
|
Honoraria - Amgen; Kyowa Hakko Kirin; Merck |
Consulting or Advisory Role - Merck |
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Roche |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Roche |
Speakers' Bureau - Amgen; Ipsen; Lilly |
Travel, Accommodations, Expenses - Amgen; Novartis |
|
|
Travel, Accommodations, Expenses - Amgen; Merck; Roche; Servier |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - amgen; Merck; roche; sanofi; servier |
Travel, Accommodations, Expenses - amgen; Merck; roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AMGEN; MERCK; ROCHE |
|
Travel, Accommodations, Expenses - MERCK; ROCHE |
|
|
Consulting or Advisory Role - celgene; Sanofi |
Research Funding - Amgen (Inst); Celgene (Inst); Erytech Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); PAREXEL (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche; Sanofi; SERVIER |
|
|
Speakers' Bureau - Pfizer; Roche; Sanofi Pasteur; Sanofi Pasteur; Sanofi Pasteur |
Travel, Accommodations, Expenses - Amgen; Amgen; Ipsen; Pfizer |
|
|
Honoraria - Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Merck |
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
Teresa Fernandez Rodriguez |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Merck; Roche; Sanofi |